ReviewPulmonary circulation2026
Supraventricular Arrhythmias in Pulmonary Hypertension: A Comprehensive Review From Preclinical Evidence to Clinical Practice.
Review in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ventricular arrhythmogenesis in pulmonary hypertension: From right ventricular remodeling to clinical implications.Physiological reports · 2026Review
- Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary Hypertension (PH) is a chronic disease that causes significant structural deterioration in the right atrium and ventricle. In the past 1-2 decades, life expectancy in patients with PH has increased due to improved awareness, diagnosis and advancements in treatment. Increasingly, PH is recognized in older patients with comorbidities. With the changing demographics, supraventricular arrhythmias (SVAs), especially atrial fibrillation and flutter, are emerging as important outcomes in PH. Here, we comprehensively summarize findings from preclinical and clinical studies to define the mechanistic drivers and clinical implications of SVA. In sum, we propose early recognition and targeted management of SVA is important to improve quality of life, morbidity and mortality in patients with PH.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.